Calcified Tissue International

, Volume 83, Issue 4, pp 251–259 | Cite as

Acid-Suppressive Medications and Risk of Bone Loss and Fracture in Older Adults

  • Elaine W. YuEmail author
  • Terri Blackwell
  • Kristine E. Ensrud
  • Teresa A. Hillier
  • Nancy E. Lane
  • Eric Orwoll
  • Douglas C. Bauer


Recent studies have suggested an increased fracture risk with acid-suppressive medication use. We studied two cohorts of men and women over age 65 who were enrolled in the Osteoporotic Fractures in Men Study (MrOS) and the Study of Osteoporotic Fractures (SOF), respectively. We used dual-energy X-ray absorptiometry and assessed baseline use of proton pump inhibitors (PPIs) and/or H2 receptor antagonists (H2RAs) in 5,755 men and 5,339 women. Medication use and bone mineral density (BMD) were assessed, and hip and other nonspine fractures were documented. On multivariate analysis, men using either PPIs or H2RAs had lower cross-sectional bone mass. No significant BMD differences were observed among women. However, there was an increased risk of nonspine fracture among women using PPIs (relative hazard [RH] = 1.34, 95% confidence interval [CI] 1.10–1.64). PPI use was also associated with an increased risk of nonspine fracture in men but only among those who were not taking calcium supplements (RH = 1.49, 95% CI 1.04–2.14). H2RA use was not associated with nonspine fractures, and neither H2RA use nor PPI use was associated with incident hip fractures in men or women. The use of PPIs in older women, and perhaps older men with low calcium intake, may be associated with a modestly increased risk of nonspine fracture.


Bone density Fracture H2 receptor antagonist Proton pump inhibitor 



The SOF is supported by National Institutes of Health funding. The following institutes provide support: the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) and the National Institute on Aging (NIA) under grant numbers AG05407, AR35582, AG05394, AR35584, AR35583, R01 AG005407, R01 AG027576-22, 2 R01 AG005394-22A1, and 2 R01 AG027574-22A1. The MrOS is supported by National Institutes of Health (NIH) funding. The following institutes provide support: NIAMS, NIA, the National Center for Research Resources, and the NIH Roadmap for Medical Research under grant numbers U01 AR45580, U01 AR45614, U01 AR45632, U01 AR45647, U01 AR45654, U01 AR45583, U01 AG18197, U01-AG027810, and UL1 RR024140. Midcareer mentoring awards have been given to D. C. B. and N. E. L. (K24-AR-04884).

Conflict of interest statement

Dr. Bauer has received research funding from Merck, Amgen, Proctor and Gamble, and has consultancies for Merck, Zelos, and Tethys. All other authors have no conflicts of interest.


  1. 1.
    IMS Health (2005) Leading therapy classes by pharmaceutical sales. Accessed January 2008
  2. 2.
    Miyamoto M, Haruma K, Kuwabara M, Nagano M, Okamoto T, Tanaka M (2007) Long-term gastroesophageal reflux disease therapy improves reflux symptoms in elderly patients: five-year prospective study in community medicine. J Gastroenterol Hepatol 22:639–644PubMedGoogle Scholar
  3. 3.
    Laine L, Ahnen D, McClain C, Solcia E, Walsh JH (2000) Potential gastrointestinal effects of long-term acid suppression with proton pump inhibitors. Aliment Pharmacol Ther 14:651–668PubMedCrossRefGoogle Scholar
  4. 4.
    Laheij RJ, Sturkenboom MC, Hassing RJ, Dieleman J, Stricker BH, Jansen JB (2004) Risk of community-acquired pneumonia and use of gastric acid-suppressive drugs. JAMA 292:1955–1960PubMedCrossRefGoogle Scholar
  5. 5.
    Graziani G, Badalamenti S, Como G, Gallieni M, Finazzi S, Angelini C, Brancaccio D, Ponticelli C (2002) Calcium and phosphate plasma levels in dialysis patients after dietary Ca-P overload. Role of gastric acid secretion. Nephron 91:474–479PubMedCrossRefGoogle Scholar
  6. 6.
    Graziani G, Como G, Badalamenti S, Finazzi S, Malesci A, Gallieni M, Brancaccio D, Ponticelli C (1995) Effect of gastric acid secretion on intestinal phosphate and calcium absorption in normal subjects. Nephrol Dial Transplant 10:1376–1380PubMedGoogle Scholar
  7. 7.
    O’Connell MB, Madden DM, Murray AM, Heaney RP, Kerzner LJ (2005) Effects of proton pump inhibitors on calcium carbonate absorption in women: a randomized crossover trial. Am J Med 118:778–781PubMedCrossRefGoogle Scholar
  8. 8.
    Ensrud KE, Duong T, Cauley JA, Heaney RP, Wolf RL, Harris E, Cummings SR (2000) Low fractional calcium absorption increases the risk for hip fracture in women with low calcium intake. Study of Osteoporotic Fractures Research Group. Ann Intern Med 132:345–353PubMedGoogle Scholar
  9. 9.
    Nordin BE (1997) Calcium and osteoporosis. Nutrition 13:664–686PubMedCrossRefGoogle Scholar
  10. 10.
    Cui GL, Syversen U, Zhao CM, Chen D, Waldum HL (2001) Long-term omeprazole treatment suppresses body weight gain and bone mineralization in young male rats. Scand J Gastroenterol 36:1011–1015PubMedCrossRefGoogle Scholar
  11. 11.
    Grisso JA, Chiu GY, Maislin G, Steinmann WC, Portale J (1991) Risk factors for hip fractures in men: a preliminary study. J Bone Miner Res 6:865–868PubMedGoogle Scholar
  12. 12.
    Vestergaard P, Rejnmark L, Mosekilde L (2006) Proton pump inhibitors, histamine h(2) receptor antagonists, and other antacid medications and the risk of fracture. Calcif Tissue Int 79:76–83PubMedCrossRefGoogle Scholar
  13. 13.
    Yang YX, Lewis JD, Epstein S, Metz DC (2006) Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA 296:2947–2953PubMedCrossRefGoogle Scholar
  14. 14.
    Cummings SR, Black DM, Nevitt MC, Browner WS, Cauley JA, Genant HK, Mascioli SR, Scott JC, Seeley DG, Steiger P et al (1990) Appendicular bone density and age predict hip fracture in women. The Study of Osteoporotic Fractures Research Group. JAMA 263:665–668PubMedCrossRefGoogle Scholar
  15. 15.
    Vogt MT, Rubin DA, Palermo L, Christianson L, Kang JD, Nevitt MC, Cauley JA (2003) Lumbar spine listhesis in older African American women. Spine J 3:255–261PubMedCrossRefGoogle Scholar
  16. 16.
    Blank JB, Cawthon PM, Carrion-Petersen ML, Harper L, Johnson JP, Mitson E, Delay RR (2005) Overview of recruitment for the osteoporotic fractures in men study (MrOS). Contemp Clin Trials 26:557–568PubMedCrossRefGoogle Scholar
  17. 17.
    Orwoll E, Blank JB, Barrett-Connor E, Cauley J, Cummings S, Ensrud K, Lewis C, Cawthon PM, Marcus R, Marshall LM, McGowan J, Phipps K, Sherman S, Stefanick ML, Stone K (2005) Design and baseline characteristics of the osteoporotic fractures in men (MrOS) study—a large observational study of the determinants of fracture in older men. Contemp Clin Trials 26:569–585PubMedCrossRefGoogle Scholar
  18. 18.
    Pahor M, Chrischilles EA, Guralnik JM, Brown SL, Wallace RB, Carbonin P (1994) Drug data coding and analysis in epidemiologic studies. Eur J Epidemiol 10:405–411PubMedCrossRefGoogle Scholar
  19. 19.
    Ensrud KE, Palermo L, Black DM, Cauley J, Jergas M, Orwoll ES, Nevitt MC, Fox KM, Cummings SR (1995) Hip and calcaneal bone loss increase with advancing age: longitudinal results from the Study of Osteoporotic Fractures. J Bone Miner Res 10:1778–1787PubMedCrossRefGoogle Scholar
  20. 20.
    Steiger P, Cummings SR, Black DM, Spencer NE, Genant HK (1992) Age-related decrements in bone mineral density in women over 65. J Bone Miner Res 7:625–632PubMedGoogle Scholar
  21. 21.
    Mackey DC, Lui LY, Cawthon PM, Bauer DC, Nevitt MC, Cauley JA, Hillier TA, Lewis CE, Barrett-Connor E, Cummings SR (2007) High-trauma fractures and low bone mineral density in older women and men. JAMA 298:2381–2388PubMedCrossRefGoogle Scholar
  22. 22.
    Washburn RA, Smith KW, Jette AM, Janney CA (1993) The Physical Activity Scale for the Elderly (PASE): development and evaluation. J Clin Epidemiol 46:153–162PubMedCrossRefGoogle Scholar
  23. 23.
    Block G, Subar AF (1992) Estimates of nutrient intake from a food frequency questionnaire: the 1987 National Health Interview Survey. J Am Diet Assoc 92:969–977PubMedGoogle Scholar
  24. 24.
    Collett D (1994) Time-dependent variables. Chapman & Hall, LondonGoogle Scholar
  25. 25.
    Allison P (1995) Estimating Cox regression models with PROC PHREG. SAS Institute, Cary, NCGoogle Scholar
  26. 26.
    Schafer JL (1999) Multiple imputation: a primer. Stat Methods Med Res 8:3–15PubMedCrossRefGoogle Scholar
  27. 27.
    Rubin DB (1997) Estimating causal effects from large data sets using propensity scores. Ann Intern Med 127:757–763PubMedGoogle Scholar
  28. 28.
    Tuukkanen J, Vaananen HK (1986) Omeprazole, a specific inhibitor of H+-K+-ATPase, inhibits bone resorption in vitro. Calcif Tissue Int 38:123–125PubMedCrossRefGoogle Scholar
  29. 29.
    Mizunashi K, Furukawa Y, Katano K, Abe K (1993) Effect of omeprazole, an inhibitor of H+, K+-ATPase, on bone resorption in humans. Calcif Tissue Int 53:21–25PubMedCrossRefGoogle Scholar
  30. 30.
    Recker RR (1985) Calcium absorption and achlorhydria. N Engl J Med 313:70–73PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2008

Authors and Affiliations

  • Elaine W. Yu
    • 1
    Email author
  • Terri Blackwell
    • 2
  • Kristine E. Ensrud
    • 3
    • 4
  • Teresa A. Hillier
    • 5
  • Nancy E. Lane
    • 6
  • Eric Orwoll
    • 7
  • Douglas C. Bauer
    • 8
  1. 1.Endocrine DivisionMassachusetts General HospitalBostonUSA
  2. 2.California Pacific Medical Center Research InstituteSan FranciscoUSA
  3. 3.Center for Chronic Disease Outcomes ResearchVA Medical CenterMinneapolisUSA
  4. 4.Department of Epidemiology and Community HealthUniversity of MinnesotaMinneapolisUSA
  5. 5.Kaiser Permanente Center for Health Research, Northwest and HawaiiPortlandUSA
  6. 6.University of CaliforniaDavisUSA
  7. 7.Oregon Health and Science UniversityPortland USA
  8. 8.University of CaliforniaSan FranciscoUSA

Personalised recommendations